ASH 2016 | Defibrotide to treat hepatic veno-occlusive disease/sinusoidal obstruction syndrome in AML & ALL

Paul Richardson

Paul Richardson, MD of the Dana-Farber Cancer Institute, Boston, MA discusses a subgroup analysis from the defibrotide expanded-access program for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) post-hematopoietic stem cell transplantation (HSCT) in patients with acute leukemias, specifically acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Prof. Richardson explains that the day 100 survival rates are respectable with approximately 46-47% for both groups. The tolerability of defibrotide and the treatment-related adverse event profile was also favorable for both groups. Therefore, they were able to demonstrate that there was a consistent and significant clinical benefit seen in terms of overall survival (OS) and complete response (CR) for the acute leukemia populations with defibrotide therapy in the presence of severe VOD/SOS post-transplantation. Prof. Richardson further discusses the question of when to give defibrotide. Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.

Share this video